Human cytomegalovirus GB polypeptide
AssigneePfizer Inc.
InventorsYuhang Liu, Ye Che, Xiaoyuan Sherry Chi, Philip Ralph Dormitzer, Jennifer Anne Nicki, Xiaojie Yao
Life of this patent
Estimating the term…
Abstract
The present invention comprises mutants of a wild-type cytomegalovirus (CMV) glycoprotein B (gB) protein that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB), compositions including the mutants and uses thereof. In some embodiments, the mutant is stabilized in a conformation alternative to the gB postfusion conformation.
Claims37
An engineered mutant of a wild-type cytomegalovirus (CMV) glycoprotein B (gB) protein, wherein said mutant comprises at least two amino acid mutations, and wherein said at least two amino acid mutations comprise at least one engineered disulfide mutation selected from the group consisting of:
- D217C and Y589C;
- M371C and W506C;
- and N524C and M684C;
- and wherein the numbering of the engineered mutations is relative to SEQ ID NO:1 numbering.
Dependencies are inferred from the claim text.